Expertise in
207
conditions

Dr. Robert Hopkin

Medical Genetics | Pediatrics
Children's Hospital Medical Center
3333 Burnet Ave, 
Cincinnati, OH 
Expertise in
207
conditions
Children's Hospital Medical Center
3333 Burnet Ave, 
Cincinnati, OH 

Overview

Robert Hopkin is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Cincinnati, Ohio.

Dr. Hopkin is highly rated in 207 conditions, according to our data. His clinical expertise encompasses Fabry Disease, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Microcephaly, and Orchiectomy.

He is actively involved in clinical research, co-authoring 133 peer reviewed articles and participating in 4 clinical trials.

Specialties

Medical Genetics
Pediatrics

Licenses

Clinical Genetics in OH

Hospital Affiliations

Cincinnati Children's Hospital Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

CHILDREN'S HOSPITAL MEDICAL CENTER
3333 Burnet Ave, Cincinnati, OH 45229

Additional Areas of Focus

Dr. Hopkin has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects With Fabry Disease (STAAR)
Enrollment Status: Completed
Publish Date: April 14, 2026
Intervention Type: Biological
Study Drug: ST-920
Study Phase: Phase 1/Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader- Willi Syndrome
Enrollment Status: Terminated
Publish Date: October 19, 2023
Intervention Type: Drug
Study Drug: RAD011
Study Phase: Phase 2/Phase 3
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Phase 3 Open-Label Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa (PRX-102) 2mg/kg IV Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy Fabrazyme® or Replagal™
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drug: Pegunigalsidase Alfa
Study Phase: Phase 3
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Biological
Study Drugs: PRX-102 (Pegunigalsidase Alfa), Agalsidase Beta
Study Phase: Phase 3
View 3 Less Clinical Trials

133 Total Publications

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.
Journal: Therapeutic advances in rare disease
Published: July 02, 2025
Similar Doctors
Expertise in
200
conditions
Dr. Howard Saal
Medical Genetics | Pediatrics
Expertise in
200
conditions
Dr. Howard Saal
Medical Genetics | Pediatrics
Referral may be required
3333 Burnet Ave, Ml 4006, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4760
Languages Spoken:
English
See accepted insurances

Howard Saal is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Cincinnati, Ohio. Dr. Saal is highly rated in 200 conditions, according to our data. His clinical expertise encompasses Achondroplasia, Acrofacial Dysostosis Rodriguez Type, Treacher Collins Syndrome, and Acrofacial Dysostosis Catania Type.

Expertise in
120
conditions
Dr. Kathryn Weaver
Medical Genetics | Pediatrics
Expertise in
120
conditions
Dr. Kathryn Weaver
Medical Genetics | Pediatrics
Referral may be required

Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4200
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Kathryn Weaver is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Cincinnati, Ohio. She has been practicing medicine for over 17 years. Dr. Weaver is highly rated in 120 conditions, according to our data. Her clinical expertise encompasses Acrofacial Dysostosis Catania Type, RASopathies, Costello Syndrome, and Noonan Syndrome.

Expertise in
146
conditions
Dr. Anne M. Slavotinek
Medical Genetics | Pediatrics
Expertise in
146
conditions
Dr. Anne M. Slavotinek
Medical Genetics | Pediatrics
Referral may be required

Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (0.1 miles away)
513-636-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anne Slavotinek is a Medical Genetics specialist and a Pediatrics provider practicing medicine in Cincinnati, Ohio. Dr. Slavotinek is highly rated in 146 conditions, according to our data. Her clinical expertise encompasses Floating-Harbor Syndrome, Retinopathy Pigmentary Mental Retardation, Bardet-Biedl Syndrome, and Micrognathia. Dr. Slavotinek is currently accepting new patients.

Frequently Asked Questions about Dr. Robert Hopkin

How do I make an appointment with Dr. Robert Hopkin?

You can book an appointment with Dr. Robert Hopkin by calling their office at 513-636-4200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Robert Hopkin a top-rated expert for Fabry Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Robert Hopkin is classified as an Elite expert for Fabry Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Robert Hopkin specialize in?

While Dr. Robert Hopkin is a Medical Genetics, they have specific expertise in Fabry Disease, Neurofibromatosis Type 1 (NF1), and Neurofibromatosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Medical Genetics.

Does Dr. Robert Hopkin participate in research or clinical trials?

Yes. Dr. Robert Hopkin has published 133 articles and abstracts on conditions like Fabry Disease. You can view a list of Dr. Robert Hopkin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Robert Hopkin accept my insurance?

Dr. Robert Hopkin accepts most major insurance plans, including Anthem BCBS and Arkansas Health and Wellness. We recommend calling the office directly at 513-636-4200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hopkin's expertise for a condition
ConditionClose
View All 19 Distinguished Conditions
View All 187 Advanced Conditions
View All 93 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile